breast cancer

News

Roche bounces back in PIK3 with inavolisib data

A few years ago, Roche abandoned the development of its lead PIK3CA-targeting drug taselisib on safety grounds, allowing rival Novartis to beat it to market, but now it ha

News

AZ first to AKT finish line, but FDA clears narrow label

AstraZeneca has claimed FDA approval for its first-in-class pan-AKT inhibitor capivasertib, getting a green light for the drug as a treatment for breast cancer, but with a

Oncology

Resilience, empathy, and gratitude. A personal battle with b...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Nataliya Andreychuk, CEO of Viseven, about her personal battle with breast cancer.

News

Generic breast cancer drug cleared for prevention in England

Almost 30 years after it was first licensed as a treatment for breast cancer, aromatase inhibitor anastrozole has been cleared for preventive use in women at high risk of

News

NICE turns down Enhertu in “devastating” move, says charity

AstraZeneca and Daiichi Sankyo’s Enhertu should not be made available via the NHS for HER2-low metastatic or unresectable breast cancer after chemotherapy, according to pr

News

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

Armed with the first phase 3 data for their TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan as a second-line treatment for breast cancer, AstraZeneca

Roche bounces back in PIK3 with inavolisib data

AZ first to AKT finish line, but FDA clears narrow label

Resilience, empathy, and gratitude. A personal battle with b...

Generic breast cancer drug cleared for prevention in England

NICE turns down Enhertu in “devastating” move, says charity

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

breast cancer

Editor's Picks